Marker Therapeutics Inc (MRKR)

[poods]

In the early days of immunotherapy, it was thought that chemotherapy would likely suppress an anti-tumor immune response. That is likely true to some degree but we now know that this is a double edge sword. Chemotherapy can induce immunogenic cell death, increase MHC expression, eliminate T-reg and MDSC. However it can also dampen T-cell responses. That is the beauty of MRKR's therapy. The immune response against multiple TAAs is generated ex vivo in a G-Rex incubator while the chemo kills tumor cells and prepares the tumor microenvironment. Then we hit the tumor with fully primed healthy T-cells, which then also clearly initiates further immune responses to other tumor associated antigens, likely those we have measured along with neoantigen responses that we have not measured.
I think that is the source of the responses we are seeing to date in pancreatic cancer. Raising the dose of cells, the number of doses and the antigens targeted may further amplify the impact of Multi-TAA.
I think we're all in for an exciting ride.
Congrats to those who are holding on and supporting this company. I think this company is about to change cancer medicine in a big way.